LEBANON, N.H.--(BUSINESS WIRE)--Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that it is nearing completion of the addition of more than 50,000 square feet to its headquarters and research campus in Lebanon, New Hampshire.

黎巴嫩新罕布什尔州——（商业新闻短讯）——Adimab，LLC是全人类单克隆抗体和多特异性抗体发现和工程的全球领导者，今天宣布，其位于新罕布什尔州黎巴嫩的总部和研究园区新增50000多平方英尺的工程即将完工。

Over the past seven years, Adimab has added more than 400 royalty bearing therapeutic programs. To accommodate this continual growth, Adimab has increased headcount by approximately 40% over the past three years..

在过去的七年中，Adimab增加了400多个含版税的治疗计划。为了适应这种持续增长，Adimab在过去三年中将员工人数增加了约40%。。

“We have not expanded the footprint of our main research facility since initially occupying it in 2011,” explained Eric Krauland, President and Chief Scientific Officer of Adimab. “We have grown substantially since then, in terms of both employees and capabilities. This expansion will allow us to continue to offer our partners state-of-the-art protein discovery and engineering, including GPCR target campaigns, TCR engineering, and a wide array of multispecific projects.”.

Adimab总裁兼首席科学官埃里克·克劳兰德（EricKrauland）解释说：“自2011年最初占用主要研究设施以来，我们没有扩大其足迹。”。“从那时起，我们在员工和能力方面都有了长足的发展。这一扩张将使我们能够继续为合作伙伴提供最先进的蛋白质发现和工程，包括GPCR目标活动、TCR工程和各种多特异性项目。”。

“Adimab has been consistently profitable for more than a decade, a rarity in our industry,” said Ryan McGovern, Chief Financial Officer of Adimab. “Our partner-first approach to dealmaking and technology development has resulted in persistent revenue generation, and our discipline on the expense side allows us to substantially expand our facilities without threatening our profitability.”.

Adimab首席财务官瑞安·麦戈文（RyanMcGovern）表示：“十多年来，Adimab一直保持盈利，这在我们的行业中是罕见的。”。“我们以合作伙伴为先的交易和技术开发方法产生了持续的收入，我们在费用方面的纪律使我们能够在不威胁盈利能力的情况下大幅扩大设施。”。

Technologies

技术

Antibody discovery: Adimab discovers therapeutic antibodies in IgG and single domain (HCAb) formats through our proprietary yeast-based technology. Adimab can utilize its fully human synthetic diversity as well as additional diversities from in vivo sources. Antibodies from Adimab have exquisite specificity and are utilized as monospecific and multispecific therapies as well as CAR-Ts, ADCs, and other proteins..

抗体发现：Adimab通过我们专有的基于酵母的技术发现IgG和单结构域（HCAb）形式的治疗性抗体。Adimab可以充分利用其人类合成多样性以及体内来源的其他多样性。来自Adimab的抗体具有极好的特异性，可用作单特异性和多特异性治疗以及CAR-Ts，ADC和其他蛋白质。。

Engineering: Adimab has developed and refined its engineering capabilities over thousands of lead antibody optimization efforts. The process starts with one or more partner-selected lead antibodies with the goal of optimizing potency, specificity, and/or developability. These leads can come from Adimab’s discovery process or from outside sources, typically to fix undesirable properties of antibodies from in vivo and phage-based technologies.

工程：Adimab通过数千次铅抗体优化工作开发并完善了其工程能力。该过程从一种或多种伴侣选择的先导抗体开始，目的是优化效力，特异性和/或可开发性。这些线索可能来自Adimab的发现过程或外部来源，通常用于修复体内和基于噬菌体的技术产生的抗体的不良特性。

Adimab also applies its engineering expertise to cytokines, TCRs, and other modalities..

Adimab还将其工程专业知识应用于细胞因子，TCR和其他方式。。

Multispecifics and T cell engagers: Adimab has extensive multispecific capabilities that enable a variety of partner selected formats. In addition to common light chain and fragment-based discovery and engineering, Adimab has the ability to generate large panels of multispecifics for lead selection.

多特异性和T细胞参与者：Adimab具有广泛的多特异性功能，可以实现多种合作伙伴选择的格式。除了常见的轻链和基于片段的发现和工程之外，Adimab还能够生成大量多特异性的铅选择。

Adimab also has proprietary solutions for both Fc (HC:HC) and Fab (HC:LC) heterodimerization to allow for the generation of numerous multispecific product designs with excellent developability properties. These are commonly coupled with Adimab’s highly characterized suite of CD3 and CD28 antibodies to generate multispecific T cell engagers..

Adimab还拥有Fc（HC:HC）和Fab（HC:LC）异二聚化的专有解决方案，可以生成具有优异可开发性的多种多特异性产品设计。这些通常与Adimab高度表征的CD3和CD28抗体套件结合，产生多特异性T细胞参与者。。

Complex targets workflows: Certain membrane-obligate proteins (e.g., GPCRs and ion channels) are poorly behaved outside their native membrane environment. For these targets, Adimab has developed proprietary in vitro and in vivo discovery workflows that allow for discovery against membrane-obligate proteins in their native state.

复杂的目标工作流程：某些膜专性蛋白（例如GPCR和离子通道）在其天然膜环境之外表现不佳。对于这些靶标，Adimab开发了专有的体外和体内发现工作流程，可以发现天然状态下的膜专性蛋白。

The company has employed these workflows numerous times to generate robust panels of specific antibodies to these classically difficult targets..

该公司已多次采用这些工作流程来生成针对这些经典困难目标的强大特异性抗体组。。

About Adimab

关于Adimab

Adimab is the leading provider of therapeutic antibody discovery and engineering technologies. This includes naïve discovery from synthetic libraries in yeast or B cells (mice, llama, and humans), antibody engineering and optimization, multi-specific antibody engineering, and a portfolio of proprietary CD3 and CD28 antibodies licensed non-exclusively for multispecific applications.

Adimab是治疗性抗体发现和工程技术的领先供应商。这包括从酵母或B细胞（小鼠，美洲驼和人类）的合成文库中发现的幼稚发现，抗体工程和优化，多特异性抗体工程，以及一系列专有的CD3和CD28抗体，这些抗体非专门用于多特异性应用。

Adimab focuses solely on its partners and not on developing an internal product pipeline. Since 2009, Adimab has partnered with over 115 pharmaceutical and biotechnology companies, generating more than 525 therapeutic programs, over 70 clinical programs, and several approved products. The Adimab technology has been transferred and implemented at Biogen, GSK, Lilly, Merck, Novo Nordisk, Takeda.

Adimab专注于其合作伙伴，而不是开发内部产品管道。自2009年以来，Adimab已与115多家制药和生物技术公司合作，产生了525多个治疗计划，70多个临床计划和多个获批产品。Adimab技术已在Biogen，GSK，礼来，默克，诺和诺德，武田转让和实施。

Funded discovery partners include leading pharmaceutical companies, such as Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Regeneron, Sanofi, Takeda, Vertex and others. Adimab has also partnered with many early-stage venture-backed companies, including Dragonfly, NextPoint, Tizona, TRex Bio and others, as well as mid-size public biopharmaceutical companies such as Alector, Cullinan Oncology, Innovent, iTeos, Mersana Therapeutics, Santa Ana Bio, Scholar Rock, and others..

资助的发现合作伙伴包括领先的制药公司，如勃林格殷格翰（Boehringer Ingelheim）、百时美施贵宝（Bristol-Myers Squibb）、诺华（Novartis）、Regeneron、赛诺菲（Sanofi）、武田（Takeda）、Vertex等。Adimab还与许多早期风险投资支持的公司合作，包括蜻蜓，NextPoint，Tizona，TRex Bio等，以及中型公共生物制药公司，如Alector，Cullinan Oncology，Innovent，iTeos，Mersana Therapeutics，Santa Ana Bio，Scholar Rock等。。

Adimab’s integrated antibody discovery and engineering platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most demanding standards for affinity, epitope coverage, species cross-reactivity, and developability.

Adimab的综合抗体发现和工程平台提供了从抗原到纯化的全长人IgG的前所未有的速度。Adimab通过提供多种治疗相关抗体来提供基本优势，这些抗体满足亲和力，表位覆盖率，物种交叉反应性和可发育性的最苛刻标准。

Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements. For more information, visit http://www.adimab.com..

Adimab使其合作伙伴能够通过广泛的技术获取安排迅速扩大其生物制剂管道。有关更多信息，请访问http://www.adimab.com..